399 476
over-active bladder: early UK experienceEuropean Association of
Urology Meeting; March 20–24, Madrid, Spain. Abstract 267; 2015.
[20]
Wagg A, Foley S, Peters J, et al. Persistence and adherence with mirabegron versus antimuscarinics in overactive bladder: retro- spective analysis of a UK general practice prescription database- Ninth European Urogynaecological Association Annual Meeting; November 3–5, Amsterdam, Netherlands; 2016.
[21]
Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015;44:827–36.
[22]
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83.[23]
Khan NF, Perera R, Harper S, et al. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 2010;11:1.[24]
Andy UU, Arya LA, Smith AL, et al. Is self-reported adherence associated with clinical outcomes in women treated with anticho- linergic medication for overactive bladder? Neurourol Urodyn 2016;35:738–42.
[25] Pindoria N, Malde S, Nowers J, et al. Persistence with mirabegron
therapy for overactive bladder: a real life experience. Neurourol
Urodyn. In press.
http://dx.doi.org/10.1002/nau.22943 .[26]
Duckett J, Balachandran A. Tolerability and persistence in a large, prospective case series of women prescribed mirabegron. Int Uro- gynecol J 2016;27:1163–7.
[27]
Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2010;105: 1276–82.
[28]
Tarn DM, Heritage J, Paterniti DA, et al. Physician communication when prescribing new medications. Arch Intern Med 2006;166: 1855–62.
[29]
Campbell UB, Stang P, Barron R. Survey assessment of continuation of and satisfaction with pharmacological treatment for urinary incontinence. Value Health 2008;11:726–32.[30]
Dmochowski RR, Newman DK. Impact of overactive bladder on women in the United States: results of a national survey. Curr Med Res Opin 2007;23:65–76.[31]
Rudy D, Cline K, Harris R, et al. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU Int 2006;97:540–6.[32] National Institute for Health and Care Excellence. Mirabegron for
treating symptoms of overactive bladder. Technology appraisal
guidance TA290. London, UK: NICE; 2013.
www.nice.org.uk/ guidance/ta290E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 3 8 9 – 3 9 9
399